A Novel Missense Variant of ZC3H12A in Pulmonary Arterial Hypertension.

IF 1.1 Circulation reports Pub Date : 2025-01-31 eCollection Date: 2025-03-10 DOI:10.1253/circrep.CR-25-0007
Ryotaro Asano, Makoto Okazawa, Tomohiko Ishibashi, Xin Ding, Keiko Ohta-Ogo, Kotaro Akaki, Saori Umeki-Mizushima, Akiko Yamagishi, Tadakatsu Inagaki, Ai Yaku, Shinya Fujisaki, Takatoyo Kiko, Kinta Hatakeyama, Osamu Takeuchi, Takeshi Ogo, Yoshikazu Nakaoka
{"title":"A Novel Missense Variant of <i>ZC3H12A</i> in Pulmonary Arterial Hypertension.","authors":"Ryotaro Asano, Makoto Okazawa, Tomohiko Ishibashi, Xin Ding, Keiko Ohta-Ogo, Kotaro Akaki, Saori Umeki-Mizushima, Akiko Yamagishi, Tadakatsu Inagaki, Ai Yaku, Shinya Fujisaki, Takatoyo Kiko, Kinta Hatakeyama, Osamu Takeuchi, Takeshi Ogo, Yoshikazu Nakaoka","doi":"10.1253/circrep.CR-25-0007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Because Regnase-1, encoded by <i>ZC3H12A</i>, suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify <i>ZC3H12A</i> variants in patients with PAH.</p><p><strong>Methods and results: </strong>We analyzed whole-genome sequence data of patients with PAH to search for disease-associated <i>ZC3H12A</i> variants. The Regnase-1 p.D426G variant was identified in 2 patients, 1 of whom presented with prominent infiltration of inflammatory cells in the lung. The protein level of the variant was decreased in vitro.</p><p><strong>Conclusions: </strong>We identified a novel missense variant of <i>ZC3H12A</i> that is directly involved in regulating inflammation in patients with PAH.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 3","pages":"207-211"},"PeriodicalIF":1.1000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890303/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1253/circrep.CR-25-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/10 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Because Regnase-1, encoded by ZC3H12A, suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify ZC3H12A variants in patients with PAH.

Methods and results: We analyzed whole-genome sequence data of patients with PAH to search for disease-associated ZC3H12A variants. The Regnase-1 p.D426G variant was identified in 2 patients, 1 of whom presented with prominent infiltration of inflammatory cells in the lung. The protein level of the variant was decreased in vitro.

Conclusions: We identified a novel missense variant of ZC3H12A that is directly involved in regulating inflammation in patients with PAH.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肺动脉高压中一种新的错义变异ZC3H12A。
背景:由于由ZC3H12A编码的regase -1通过控制促炎细胞因子抑制肺动脉高压(PAH)的发展,我们旨在鉴定PAH患者中的ZC3H12A变异。方法和结果:我们分析了PAH患者的全基因组序列数据,寻找与疾病相关的ZC3H12A变异。Regnase-1 p.D426G变异在2例患者中被发现,其中1例患者表现为肺部明显的炎症细胞浸润。该变异的蛋白水平在体外降低。结论:我们发现了一种新的ZC3H12A错义变体,它直接参与调节PAH患者的炎症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Impact of Snowfall on Ambulance Response Times to Out-of-Hospital Cardiac Arrest - Nationally-Representative Population-Based Registry Analysis, 2009-2019. Significance of Prehospital 12-Lead Electrocardiogram Transmission - Trial Utilizing an Established Smartphone Communication Application for Acute Stroke Management. Japanese Nationwide Survey of New Heart Failure Drug Prescriptions by Pediatric Cardiologists. Clinical Trial on the Usefulness of an Intensive Low-Density Lipoprotein Cholesterol Treatment and Familial Hypercholesterolemia Screening Clinical Pathway for Acute Coronary Syndrome: The Hokuriku-plus Acute Coronary Syndrome Registry Study - Rationale and Study Design. Evaluation of the 1-Year Efficacy and Tolerability of Inclisiran in Coronary Artery Disease Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1